<DOC>
	<DOCNO>NCT01083875</DOCNO>
	<brief_summary>The purpose study determine effect 0.5 % amlexanox oral rinse compare vehicle control mucositis-related ulceration erythema ( objective score ) mucositis-related oral pain ( subjective score ) . A secondary objective evaluate safety 0.5 % amlexanox oral rinse determine frequency treatment-emergent drug-related adverse event clinical laboratory abnormality .</brief_summary>
	<brief_title>Study Determine Effects Treatment With Amlexanox 0.5 % Oral Rinse Solution Oral Mucositis Associated With Radiation Therapy Cancer Head Neck Region</brief_title>
	<detailed_description />
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Amlexanox</mesh_term>
	<criteria>1 . Patient 18 year age old ; 2 . Patient histologically document diagnosis cancer head neck region ; 3 . Patient receive course radiation therapy ( without concomitant chemotherapy ) plan dose least 60 Gy 67 week , plan field involve least 50 % oral mucosa ; This criterion amend ( Amendment 01 date August 28 , 2000 ) read follow : 3 . Amended : Patient high risk develop radiationinduced mucositis . For purpose study , highrisk patient define : 1. patient receive course radiation therapy ( without concomitant chemotherapy ) plan dose least 60 Gy 67 week , 2. plan field involve least 40 % oral oropharyngeal mucosa visible direct inspection ; 4 . Patient Karnofsky Performance Scale ( KPS ) score 60 % ; 5 . Patient willing able cooperate protocol include rinse oral cavity investigational vehicle oral rinse 6 time per day . 6 . The patient guardian capable providing inform consent . 7 . If female , subject undergone urine pregnancy test negative result , agree practice effective method contraception duration study . Exclusion criteria 1 . Patient previous radiation therapy oral mucosa ; 2 . Patient receive hyperfractionated radiation therapy ; 3 . Patient active oral H. simplex lesion , oral candidiasis , oral mucositis due disease process ; 4 . Patient uncontrolled infection ; 5 . Patient HIV , Hepatitis B ( HBV ) ( measure HBsAg ) Hepatitis C ( HCV ) infection ; 6 . Patient recover oral toxicity attributable prior treatment ; 7 . Patient abnormal laboratory value meet follow criterion : Serum creatinine great 2 x upper limit normal Total bilirubin great 3 x upper limit normal ; SGOT great 3 x upper limit normal ; LDH great 3 x upper limit normal ; 8 . Patient known sensitivity study preparation ingredient ; 9 . Patient participate clinical research study within last 30 day prior enrollment ; 10 . Patient unable communicate cooperate investigator due language problem , poor mental development , reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Radiation</keyword>
	<keyword>mucositis</keyword>
	<keyword>head neck carcinoma</keyword>
	<keyword>oral rinse</keyword>
	<keyword>amlexanox</keyword>
	<keyword>MuGard</keyword>
</DOC>